back to press releases

Quanterix CEO David Okrongly To Present At Biotech Showcase 2011

Cambridge, MA – Quanterix, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced that David Okrongly, Ph.D., President and Chief Executive Officer, will present at the 3rd annual Biotech Showcase 2011 held January 10-12 in San Francisco by EBD Group, the leading partnering firm for the global life science industry.

Held during the world’s largest gathering of life science industry executives and investors, Biotech Showcase provides public and private life science companies the opportunity to present to their key audiences. Dr. Okrongly will discuss Quanterix’s proprietary Single Molecule Array (SiMoA™) technology, which offers more than 1,000-fold greater sensitivity for improved biomarker validation and faster, more precise results for earlier disease detection at lower cost.

Quanterix’s company presentation is scheduled for Monday, January 10th at 4:45 pm in the Mission II Room of the Parc 55 Wyndham Hotel.

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today’s analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness. Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit